Sputum Color Could Help Monitor Bronchiectasis Inflammation
Tracking sputum changes offers a practical way for patients to gauge airway inflammation in bronchiectasis.
Updated on Oct. 28, 2026 in Asthma
Live Poll
Do you believe tracking physical symptoms at home is a reliable way to manage chronic health?
Researchers have identified a link between patient-reported sputum color and airway inflammation in individuals with bronchiectasis. This finding suggests that monitoring sputum appearance could help better track disease activity in those managing this chronic condition.
Why it matters
Understanding the correlation between sputum color and inflammation helps patients and clinicians more accurately gauge the underlying severity of airway issues. This insight offers a simple, patient-driven tool to monitor disease progression and the potential impact of ongoing treatments.
A post hoc analysis of the 326-patient ASPEN trial shows that darker sputum correlates with significantly higher levels of neutrophil serine protease activity. The study, which categorized patient sputum as mucoid, mucopurulent, or purulent, confirms a physiological basis for these visual observations.
The players
CHEST
A professional society focused on clinical chest medicine and respiratory health that hosts annual research meetings.
FDA
The federal agency responsible for regulating medications like brensocatib to ensure they are safe and effective for public use.
The details
The analysis indicates that as sputum shifts from mucoid to purulent, neutrophil serine protease activity increases correspondingly, reflecting heightened airway inflammation. Brensocatib, a dipeptidyl peptidase 1 inhibitor approved by the FDA in August 2025, works by curbing these inflammatory enzymes to reduce overall airway damage. By validating sputum color as a biomarker for these enzymes, the findings highlight a way to objectively track how well a treatment manages severe pulmonary exacerbations.
Timeline
August 2025: The FDA approved brensocatib for the treatment of bronchiectasis.
October 18-21, 2026: Researchers presented the study findings at the CHEST 2026 Annual Meeting in Phoenix, Arizona.
Health Landscape
This analysis builds upon the ASPEN trial to refine how clinicians and patients monitor bronchiectasis in real time. It marks a shift toward using accessible, patient-reported metrics to supplement more complex laboratory testing in managing chronic airway inflammation.
If you are managing bronchiectasis, tracking changes in your sputum color can provide a useful gauge of your current inflammation level. Discuss these patterns with your doctor to determine if they should influence your monitoring schedule or current treatment plan.
The takeaway
Sputum color acts as a practical indicator of airway inflammation levels in patients with bronchiectasis. Keeping a simple log of your daily symptoms to share with your physician can provide valuable data during your next checkup.
Further reading
For additional insights on managing chronic airway conditions, visit our Asthma section.
More information
Review the full details in the CHEST news release on sputum research.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you believe tracking physical symptoms at home is a reliable way to manage chronic health?
